
BostonGene Partners with Johns Hopkins University School of Medicine Furthering Strategic Research Partnerships
BostonGene, a provider of AI-driven molecular and immune profiling solutions, has announced a new master agreement with the esteemed Johns Hopkins University School of Medicine (JHUSOM). The collaboration aims to advance multiple clinical research projects and drive the exploration of novel precision medicine approaches within the field of healthcare. The company has signed similar agreements with with New York’s Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital Cancer Center.
Under this strategic partnership, JHUSOM will collaborate closely with BostonGene in conducting a comprehensive molecular characterization study of patients’ tumors, microenvironments, and immune systems. The focus is on understanding the predictive value of these factors in response to various treatment modalities. BostonGene’s advanced artificial intelligence solutions will play a pivotal role by offering detailed analysis, interpretation, and visualization of vast datasets sourced from genomic, transcriptomic, proteomic, and imaging studies of cancer patients.
The research initiatives will delve into a wide range of clinical topics, including:
- Somatic Alterations: Identifying significant genetic changes within the patient’s tumor.
- Protein Expression: Evaluating the levels of specific proteins that play a role in cancer.
- Tumor Clonality: Analyzing the genetic diversity within the tumor.
- Tumor Microenvironment Composition: Understanding the types of cells present in the tumor’s surroundings.
- Hereditary Predisposition: Identifying genetic factors contributing to cancer susceptibility.
- Viral Infestation: Exploring the presence of viruses within the tumor.
- Pharmacogenomics: Assessing how a patient’s genetic makeup influences their response to medications.
- Neoantigens: Predicting specific targets for personalized vaccine development.
BostonGene will employ its advanced bioinformatics capabilities to validate hypothesis-driven research, ultimately identifying targetable molecular alterations with the potential to improve cancer treatment.
BostonGene offers a cloud-based platform that combines various AI-driven molecular and immune profiling techniques such as tumor sequencing, liquid biopsy, immunoprofiling, and spatial genomics to thoroughly analyze a patient’s tumor, its microenvironment, and the host immune system. This comprehensive analysis helps identify personalized treatment targets. The company operates a CLIA-certified, CAP-accredited, and New York State-approved laboratory.
Dr. Nathan Fowler, Chief Medical Officer at BostonGene, expressed his enthusiasm for the collaboration, stating, “We’re honored to collaborate with JHUSOM to provide our AI-based molecular and immune profiling techniques that comprehensively analyze the tumor, microenvironment, and immune system to uncover treatable targets to personalize therapy for patients. This collaboration supports our mission to support doctors in finding the most effective strategy for personalized treatment options for their patients.”